

# DEXCOM INC.

ISIN: US2521311074 WKN: 252131107 Asset Class: Stock

## Company

2022/05/24 20:03:31

**Dexcom**<sup>®</sup>  
CONTINUOUS GLUCOSE MONITORING

Price  
**285.37**  
USD

Difference  **-11.90%(-38.55)**



## Contact Details

DEXCOM INC. Tel: 1-858-200-0200  
-- Fax: -  
6340 Sequence Drive Web: <http://www.dexcom.com>  
92121 San Diego E-mail: -

## Company Profile

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2021		2020		2019	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	3,684,400,000		3,424,800,000		1,969,400,000	
Common stock capital		100,000		100,000		100,000
Fixed assets	1,179,200,000		957,900,000		425,600,000	
Equity capital of a company		2,251,500,000		1,826,500,000		882,600,000
Cash and cash equivalents	1,052,600,000		817,600,000		446,200,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		727,100,000		614,100,000		360,200,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		1,885,000,000		1,942,100,000		1,152,200,000
Different income		-		-		-
Other liabilities		27,100,000		26,900,000		5,700,000
Total assets	4,863,600,000	4,863,600,000	4,382,700,000	4,382,700,000	2,395,000,000	2,395,000,000

## Balance notes

	2021	2020	2019
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	6,300	6,400	5,200
Equity ratio	46.29%	41.68%	36.85%
Debt-equity ratio	116.02%	139.95%	171.36%

## Others

	2021	2020	2019
Tax Expense Rate	11.04%	-119.38%	2.98%

**DEXCOM INC.**

ISIN: US2521311074

WKN: 252131107

Asset Class: Stock

**Income statement**

	2021	2020	2019
<b>Turnover</b>	2,448,500,000	1,926,700,000	1,476,000,000
<b>Net income</b>	154,700,000	493,600,000	101,100,000
<b>EBIT</b>	259,941,600	281,082,000	129,022,800
<b>Operating income before taxes</b>	173,900,000	225,000,000	104,200,000
<b>Cash Flow</b>	442,500,000	475,600,000	314,500,000
<b>Net interest income</b>	-100,300,000	-71,500,000	-31,900,000
<b>Research and development expenses</b>	604,200,000	359,900,000	273,500,000
<b>Income taxes</b>	19,200,000	-268,600,000	3,100,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	368,441	285,392	269,086

**Board of Directors****Members of Management Board**

Barbara Kahn	Member of Board of Directors
Eric Topol	Member of Board of Directors
Jay Skyler	Member of Board of Directors
Bridgette Heller	Member of Board of Directors
Karen Dahut	Member of Board of Directors
Kyle Malady	Member of Board of Directors
Mark Foletta	Member of Board of Directors
Nicholas Augustinos	Member of Board of Directors
Richard Collins	Member of Board of Directors
Steven Altman	Member of Board of Directors
Kevin Sayer	Chairman of Managing Board
Andrew K. Balo	Member of Executive Committee
Barry Regan	Member of Executive Committee
Chad Patterson	Member of Executive Committee
Don Abbey	Member of Executive Committee
Jake Leach	Member of Executive Committee
Jereme Sylvain	Member of Executive Committee
Paul Flynn	Member of Executive Committee
Sadie Stern	Member of Executive Committee
Shelly Selvaraj	Member of Executive Committee
Steven R. Pacelli	Member of Executive Committee
Sumi Shrishrimal	Member of Executive Committee